CeNeS Pharmaceuticals PLC Release: Placing To Raise £4.82M, Completion Of Recruitment For Phase III Trials Of M6G And Change Of Nominated Adviser

CeNeS Pharmaceuticals plc (“CeNeS” or the “Company”), the biopharmaceutical company developing a new generation of pain management products, is pleased to announce that it has today placed an aggregate of 74,169,194 new ordinary shares ("New Ordinary Shares") at 6.5p each, to raise £4.82m (before costs) with certain institutional and other investors (the "Placing"). The New Ordinary Shares were placed on behalf of the Company by JM Finn & Co Ltd (“JM Finn”).